July 20, 2021
Ono Pharmaceutical said on July 19 that it has initiated a PII clinical trial in the US of the Bruton’s tyrosine kinase (BTK) inhibitor Velexbru (tirabrutinib) in patients with primary central nervous system lymphoma (PCNSL). In Japan, Velexbru was approved...read more